Breaking News

Flu Vaccine Candidate Confirms Enhanced Humoral and Cellular Immune Responses

September 27, 2021 • 10:37 am CDT
(Precision Vaccinations)

Maryland-based Novavax, Inc. announced the publication of complete results from a pivotal Phase 3 clinical trial of the NanoFlu™ vaccine candidate by The Lancet Infectious Diseases on September 23, 2021.

In the complete analysis, NanoFlu was well-tolerated and produced significantly enhanced humoral and cellular immune responses versus the comparator vaccine.

NanoFlu is a quadrivalent recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced in Novavax's SF9 insect cell baculovirus system.

NanoFlu uses HA amino acid protein sequences similar to the recommended wild-type circulating virus HA sequences and contains Novavax's patented saponin-based Matrix-M™ adjuvant.

"Despite high vaccination rates, limitations in the effectiveness of existing influenza vaccines leave significant disease burden unaddressed, particularly in older adults," commented Stanley C. Erck, President and Chief Executive Officer, Novavax, in a related press statement.

"These encouraging results reflect NanoFlu's promise, especially as we currently have a combination COVID-19-influenza vaccine under evaluation for protection against two life-threatening diseases simultaneously."

Novavax previously announced that NanoFlu achieved the trial's primary endpoints, demonstrating non-inferior immunogenicity to Fluzone® Quadrivalent against all four influenza virus strains included in the vaccine, while also showing both enhanced wild-type hemagglutination-inhibiting antibody responses against homologous strains (22-66% increased) and six heterologous A/H3N2 strains (34-46% increased) as compared to Fluzone Quadrivalent.

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company located in Gaithersburg, MD that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Medical Review by